Psychedelic medicine Related News
BioNxt makes bold move into proprietary MS drug formulation market
Leading bioscience accelerator BioNxt Solutions Inc. is pioneering a cutting-edge oral dissolvable Cladribine product for the treatment of Multiple Sclerosis (MS).
The Company recently acquired...
Microdosing psilocybin shows effectiveness in improving mental health
Evidence from a University of British Colombia investigation suggests that microdosing psilocybin may be an effective treatment for mental health conditions.
The Microdose.me project, published in...
Psilocybin treatment offers effective alternative for patients with depression
Novel research has signified the exciting potential of employing psychedelics to treat depression, finding that psilocybin treatment can help alleviate the impacts of the...
GCI Summit: exploring cannabis and psychedelics
This week, the GCI Summit gives global leaders the opportunity to network with the best minds in cannabis and psychedelics.
Taking place from 8 to...
Health Europa Quarterly Issue 17
Welcome to the 17th issue of Health Europa Quarterly, which focuses on the fast-growing worlds of infection prevention and control and digital health technology;...
XPhyto: Is mescaline the next big mood-modifying medicine?
Mescaline has the potential to be the next frontier in the psychedelics renaissance and represents an unprecedented opportunity to innovate a notable advancement in...
Results from world’s first MDMA alcohol use disorder trial
The world’s first trial investigating the role of MDMA therapy for the treatment of alcohol use disorder has shown positive results.
Awakn Life Sciences' Bristol...
World’s first research and cultivation facility for psychedelic mushrooms
A new partnership will see the world’s first legal research and cultivation facility dedicated exclusively to psilocybin-producing mushrooms and other plant-based psychedelics.
Field Trip Health,...
The case for mass producing psychedelic pharmaceuticals
In this article, financial journalist Marc Davis discusses the mass production of psychedelic pharmaceuticals and the steep educational curve facing medical science.
Medical science is...
Agreement for synthesis of pharmaceutical grade psychedelic compounds
A new agreement has been struck to enable the synthesis of pharmaceutical grade psychedelic compounds in a bid to ensure there is not a...
UK’s first investment fund dedicated to psychedelic healthcare
In a first for the UK, an investment fund dedicated to psychedelic healthcare has been launched.
The new fund comes as recent rigorous clinical trials...
Clinical trial explores psychedelic treatments for PTSD in veterans
A company exploring the efficacy of psychedelic treatments for PTSD in veterans has announced the international expansion of its Phase 2A clinical trials.
The Mydecine...
Combatting resistant depression with DMT and digital therapy
A wellbeing company is developing novel formulations of dimethyltryptamine (DMT) to help combat treatment resistant depression in combination with digital psychotherapy.
Nearly 264 million people live...
Psychedelics association to bridge medical establishment and industry gap
Leaders in the field of psychedelic medicine have joined forces to create the global Psychedelic Medicine Association (PMA), which aims to bridge the gap...
Ketamine therapy insights from experts in the field
A Molecular Masterclass conference delved into the benefits, research, and policy surrounding ketamine therapy.
The masterclass explored ketamine at the intersection of clinical care, research,...
The Ketamine Conference: A Molecular Masterclass
The Ketamine Conference: A Molecular Masterclass is set to take place today, featuring a host of experts in the delivery of ketamine therapy for...
Drug policy reform group urges Home Office to reschedule psilocybin
The Conservative Drug Policy Reform Group (CDPRG) has published a new report with the Adam Smith Institute outlining the potential medical benefits of psilocybin...
Medical Psychedelics Working Group to campaign for drug rescheduling
The Medical Psychedelics Working Group has now been launched in the UK to campaign for the rescheduling of all psychedelic drugs for research and...
Could ibogaine offer a revolutionary long-term solution to addiction?
Derived from the iboga plant, ibogaine is a psychoactive compound that could have huge potential as a long-term solution to addiction. ATAI Life Sciences...
Could arketamine be a breakthrough therapy for depression?
Clinical trials are being carried out to test the efficacy of arketamine as therapy for depression, with the aim of offering an alternative to...
